Palatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 receptor (MC4R) bremelanotide with tirzepatide, a glucagon-like peptide-1 ...

Several FDA-approved drugs exist for treating alcohol use disorder (AUD), but they are seldom prescribed in general practice.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

KELOWNA, BC / ACCESSWIRE / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, announces that dosing ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Intensive blood pressure control in hypertensive chronic kidney disease (CKD) provides a survival advantage and other benefits.

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" ...